Evidence map›Paper›PMID 38556092›Full record

ArticleJournal of the American Academy of Dermatology2024

Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort.

Yanmei Peng, Ashok V Kumar, Zhong Gu, Nikhila Kosuru, Jason A Wampfler, Pedro A Reck Dos Santos, Nathan Y Yu, Jonathan D'Cunha, Vinicius Ernani, Collin M Costello and 1 more

Abstract readLetter
In one paragraph

Article in Journal of the American Academy of Dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yanmei PengDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona; Department of Oncology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China.
Ashok V KumarDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
Zhong GuDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
Nikhila KosuruDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
Jason A WampflerDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Pedro A Reck Dos SantosDivision of Thoracic Surgery, Mayo Clinic, Scottsdale, Arizona.
Nathan Y YuDepartment of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona.
Jonathan D'CunhaDivision of Thoracic Surgery, Mayo Clinic, Scottsdale, Arizona.
Vinicius ErnaniDivision of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona.
Collin M CostelloDepartment of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Ping YangDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona. Electronic address: Yang.Ping@mayo.edu.

Funding

Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
ALPHA 1 AD CARRIERS AND LUNG CANCER RISKR01CA080127 · NCI · MAYO CLINIC ROCHESTER · PI YANG, PING · 2000 to 2009
$4.4M
Genetic Determinants of Lung Cancer SurvivalR01CA084354 · NCI · MAYO CLINIC ROCHESTER · PI YANG, PING · 2001 to 2012
$4.0M
Multiple Chronic Conditions and AgingR01AG052425 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2017 to 2021
$3.3M
DEVELOPMENT OF LUNG CANCER EPIDEMIOLOGY RESEARCHR03CA077118 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI YANG, PING · 1997 to 1998
–
NCI NIH HHS R01 CA080127NCI NIH HHS R01 CA084354NCI NIH HHS R03 CA077118NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG052425
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm StagingAgedCohort StudiesDrug EruptionsFemaleHumansImmune Checkpoint InhibitorsImmunotherapyMaleMiddle AgedMolecular Targeted TherapyRetrospective StudiesImmune Checkpoint Inhibitorsdermatologic toxicityimmunotherapylung cancersurvivaltargeted therapy

Identifiers

PMID38556092
PMCPMC11193628

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.